Precautions
Beryllium ore
Beryllium ore
According to the International Agency for Research on Cancer (IARC), beryllium and beryllium compounds are Category 1 carcinogens; they are carcinogenic to both animals and humans.[13] Chronic berylliosis is a pulmonary and systemic granulomatous disease caused by exposure to beryllium. Acute beryllium disease in the form of chemical pneumonitis was first reported in Europe in 1933 and in the United States in 1943. Cases of chronic berylliosis were first described in 1946 among workers in plants manufacturing fluorescent lamps in Massachusetts. Chronic berylliosis resembles sarcoidosis in many respects, and the differential diagnosis is often difficult. It occasionally killed early workers in nuclear weapons design, such as Herbert Anderson[14].
Although the use of beryllium compounds in fluorescent lighting tubes was discontinued in 1949, potential for exposure to beryllium exists in the nuclear and aerospace industries and in the refining of beryllium metal and melting of beryllium-containing alloys, the manufacturing of electronic devices, and the handling of other beryllium-containing material.
Early researchers tasted beryllium and its various compounds for sweetness in order to verify its presence. Modern diagnostic equipment no longer necessitates this highly risky procedure and no attempt should be made to ingest this highly toxic substance. Beryllium and its compounds should be handled with great care and special precautions must be taken when carrying out any activity which could result in the release of beryllium dust (lung cancer is a possible result of prolonged exposure to beryllium laden dust).
This substance can be handled safely if certain procedures are followed. No attempt should be made to work with beryllium before familiarization with correct handling procedures.
A successful test for beryllium on different surface areas has been recently developed. The procedure uses fluorescence when beryllium is bound to sulfonated hydroxybenzoquinoline to detect up to 10 times lower than the recommended limit for beryllium concentration in the work place. Fluorescence increases with increasing beryllium concentration. The new procedure has been successfully tested on a variety of surfaces.
[edit] Inhalation
Beryllium can be harmful if inhaled and the effects depend on period of exposure. If beryllium concentrations in air are high enough (greater than 100 µg/m³), an acute condition can result, called acute beryllium disease, which resembles pneumonia. Occupational and community air standards are effective in preventing most acute lung damage. Long term exposure to beryllium can increase the risk of developing lung cancer. The more common and serious health hazard from beryllium today is chronic beryllium disease (CBD), discussed below. It continues to occur in industries as diverse as metal recycling, dental laboratories, alloy manufacturing, nuclear weapons production, defense industries, and metal machine shops that work with alloys containing small amounts of beryllium.
[edit] Chronic beryllium disease (CBD)
Some people (1-15%) become sensitive to beryllium. These individuals may develop an inflammatory reaction that principally targets the respiratory system and skin. This condition is called chronic beryllium disease (CBD), and can occur within a few months or many years after exposure to higher than normal levels of beryllium (greater than 0.02 µg/m³). This disease causes fatigue, weakness, night sweats and can cause difficulty in breathing and a persistent dry cough. It can result in anorexia, weight loss, and may also lead to right-side heart enlargement and heart disease in advanced cases. Some people who are sensitized to beryllium may not have any symptoms. The disease is treatable, but not curable with traditional drugs and medicine. CBD occurs when the body's immune system recognizes beryllium particles as foreign material and mounts an immune system attack against the particles. Because these particles are typically inhaled into the lungs, the lungs become the major site where the immune system responds, they become inflamed and fill with large numbers of white blood cells that accumulate wherever beryllium particles are found. These cells form balls around the beryllium particles called “granulomas.” When enough of these develop, they interfere with the normal function of the organ. Over time, the lungs become stiff and lose their ability to help transfer oxygen from the air into the bloodstream. Patients with CBD develop difficulty inhaling and exhaling sufficient amounts of air, and the amount of oxygen in their bloodstreams falls. Treatment of such patients includes use of oxygen and medicines that try to suppress the immune system’s over-reaction to beryllium. A class of immunosuppressive medicines called glucocorticoids (example: prednisone) is most commonly used as treatment. The general population is unlikely to develop acute or chronic beryllium disease because ambient air levels of beryllium are normally very low (0.00003-0.0002 µg/m³).
[edit] Ingestion
Swallowing beryllium has not been reported to cause effects in humans because very little beryllium is absorbed from the stomach and intestines. Ulcers have been seen in dogs ingesting beryllium in their diet.
[edit] Dermatological effects
Beryllium can cause contact dermatitis. Beryllium contact with skin that has been scraped or cut may cause rashes, ulcers, or bumps under the skin called granulomas.
[edit] Effects on children
There are no studies on the health effects of children exposed to beryllium, although individual cases of CBD have been reported in children of beryllium workers from the 1940s. It is likely that the health effects seen in children exposed to beryllium will be similar to the effects seen in adults. It is unknown whether children differ from adults in their susceptibility to beryllium. It is unclear whether beryllium is teratogenic.
[edit] Detection in the body
Beryllium can be measured in the urine and blood. The amount of beryllium in blood or urine may not indicate time or quantity of exposure. Beryllium levels can also be measured in lung and skin samples. While such measurements may help establish that exposure has occurred, other tests are used to determine if that exposure has resulted in health effects. A blood test, the blood beryllium lymphocyte proliferation test (BeLPT), identifies beryllium sensitization and has predictive value for CBD. The BeLPT has become the standard test for detecting beryllium sensitization and CBD in individuals who are suspected of having CBD and to help distinguish it from similar conditions such as sarcoidosis. It is also the main test used in industry health programs to monitor whether disease is occurring among current and former workers who have been exposed to beryllium on the job. The test can detect disease that is at an early stage, or can detect disease at more advanced stages of illness as well. The BeLPT can also be performed using cells obtained from a person's lung by a procedure called "bronchoscopy."
[edit] Industrial release and occupational exposure limits
Typical levels of beryllium that industries may release into the air are of the order of 0.01 µg/m³, averaged over a 30-day period, or 2 µg/m³ of workroom air for an 8-hour work shift. Compliance with the current U.S. Occupational Safety and Health Administration (OSHA) permissible exposure limit for beryllium of 2 µg/m³ has been determined to be inadequate to protect workers from developing beryllium sensitization and CBD. The American Conference of Governmental Industrial Hygienists (ACGIH), which is an independent organization of experts in the field of occupational health, has proposed a threshold limit value (TLV) of 0.05 µg/m³ in a 2006 Notice of Intended Change (NIC). This TLV is 40 times lower than the current OSHA permissible exposure limit, reflecting the ACGIH analysis of best available peer-reviewed research data concerning how little airborne beryllium is required to cause sensitization and CBD. Because it can be difficult to control industrial exposures to beryllium, it is advisable to use any methods possible to reduce airborne and surface contamination by beryllium, to minimize the use of beryllium and beryllium-containing alloys whenever possible, and to educate people about the potential hazards if they are likely to encounter beryllium dust or fumes.